Utilization of Sacubitril/Valsartan in Real-World Settings

被引:0
作者
Efe Eworuke
Talia J. Menzin
Emily C. Welch
Joy Kolonoski
Ting-Ying Huang
机构
[1] U.S. Food and Drug Administration,Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research
[2] Harvard Medical School and Harvard Pilgrim Health Care Institute,Department of Population Medicine
来源
American Journal of Cardiovascular Drugs | 2020年 / 20卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:619 / 623
页数:4
相关论文
共 21 条
[1]  
McMurray JJV(2014)Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 993-1004
[2]  
Packer M(2016)2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Circulation 134 e282-e293
[3]  
Desai AS(2017)Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network Curr Epidemiol Rep 4 298-306
[4]  
Yancy CW(2012)Design considerations, architecture, and use of the Mini-Sentinel distributed data system Pharmacoepidemiol Drug Saf 21 23-31
[5]  
Jessup M(2012)The organizational structure and governing principles of the Food and Drug Administration’s Mini-Sentinel pilot program Pharmacoepidemiol Drug Saf 21 12-17
[6]  
Bozkurt B(2019)Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany Eur J Heart Fail 21 588-597
[7]  
Connolly JG(2011)A combined comorbidity score predicted mortality in elderly patients better than existing scores J Clin Epidemiol 64 749-759
[8]  
Wang SV(undefined)undefined undefined undefined undefined-undefined
[9]  
Fuller CC(undefined)undefined undefined undefined undefined-undefined
[10]  
Curtis LH(undefined)undefined undefined undefined undefined-undefined